Using the ResCu system for preclinical testing of KRAS G12C inhibitors

被引：0
|
作者：
Ruiz, Victor M. [1 ]
Hill, Lindsay [1 ]
Gadde, Manasa [1 ]
Bulow, Christopher [1 ]
Morri, Maurizio [1 ]
Goldner, Nicholas [1 ]
机构：
[1] ResistanceBio, San Carlos, CA USA
来源：
MOLECULAR CANCER RESEARCH | 2023年 / 21卷 / 05期
关键词：
D O I：
10.1158/1557-3125.RAS23-B030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B030
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Creating actionable neoantigens by design with KRAS(G12C) covalent inhibitors
    Maso, Lorenzo
    Hattori, Takamitsu
    Araki, Kiyomi
    Koide, Akiko
    Rajak, Epsa
    Hayman, James
    Akkapeddi, Padma
    Bang, Injin
    Neel, Benjamin G.
    Koide, Shohei
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [22] Novel natural inhibitors targeting KRAS G12C by computational study
    Jiang, Yuting
    Chen, Wanting
    Wang, Xinhui
    Zhou, Baolin
    Xie, Haoqun
    Hou, Yuanyuan
    Guo, Zhen
    Yu, Bo
    Zhong, Sheng
    Su, Xing
    ANTI-CANCER DRUGS, 2022, 33 (09) : 779 - 788
  • [23] Resistance looms for KRAS G12C inhibitors and rational tackling strategies
    Zhang, Junmin
    Zhang, Juanhong
    Liu, Qing
    Fan, Xing-Xing
    Leung, Elaine Lai-Han
    Yao, Xiao-Jun
    Liu, Liang
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [24] Development of High-throughput Assays for Testing of Potential Inhibitors of the Oncogenic G12C Mutant of KRas
    Vertessy, Beata G.
    Nyiri, Kinga
    Steger, Anett
    Koppany, Gergely
    FASEB JOURNAL, 2018, 32 (01):
  • [25] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Fukui, Sarina
    Sawada, Ryo
    Tachibana, Yusuke
    Matsui, Yohei
    Nakamura, Ryota
    Ishida, Masaki
    Kawachi, Hayato
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Furuya, Naoki
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Nishioka, Naoya
    Horinaka, Mano
    Sakai, Toshiyuki
    Uehara, Hisanori
    Yano, Seiji
    Son, Bo-Kyung
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER LETTERS, 2024, 587
  • [26] Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers
    Khan, Husain Yar
    Nagasaka, Misako
    Li, Yiwei
    Aboukameel, Amro
    Uddin, Md. Hafiz
    Sexton, Rachel
    Bannoura, Sahar
    Mzannar, Yousef
    Al-Hallak, Mohammed Najeeb
    Kim, Steve
    Beydoun, Rafic
    Landesman, Yosef
    Mamdani, Hirva
    Uprety, Dipesh
    Philip, Philip A.
    Mohammad, Ramzi M.
    Shields, Anthony F.
    Azmi, Asfar S.
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (05): : 342 - 352
  • [27] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [28] KRAS G12C mutation is not undruggable anymore
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2020, 107 (02) : 145 - 145
  • [29] Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors
    Bae, Jae Hyun
    Lew, Erin D.
    Feng, Jun
    Gonzalez-Lopez, Marcos
    Oh, Joanne
    Fagan, Patrick
    Salie, Matt
    Isley, Nick
    Lam, Richard
    Irimia, Adriana
    Nevarez, Robin
    Lin, Bingzhen
    Congdon, Taylor
    Zhang, Jingchuan
    Xuan, Dawei
    Chen, Ping
    Vernier, Jean-Michel
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [30] Concurrent inhibition of KRAS G12C and ERK1/2 overcomes acquired resistance to KRAS G12C inhibitors (G12Cis) conferred by various genetic alterations
    Wang, W.
    Lim, S. M.
    Yu, M. R.
    Cho, B. C.
    Chen, C.
    Wu, W.
    Zhang, J.
    Chen, Z. J.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S118 - S118
12345